Hero image with Pittsburgh background https://pittplusme.org/study/relay

STUDY BASICS

Are you 18-45 and newly diagnosed with type 1 diabetes? You may be eligible for a research study to see if the use of two drugs-rituximab-pvvr followed by abatacept will help to preserve remaining insulin in people with newly diagnosed diabetes. Participation involves 21 visits over 4 years. Compensation is provided.


STUDY PURPOSE

The purpose is to study the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people newly diagnosed with type 1 diabetes (T1D). Each participant will receive the rituximab-pvvr but then randomized to either abatacept or placebo.


COULD THIS STUDY BE RIGHT FOR YOU?
  • Age 18 to 45
  • Newly diagnosed with type 1 diabetes (less than 3 months ago)

WHAT PARTICIPANTS CAN EXPECT

All participants will receive investigational treatment of either rituximab-pvvr followed by abatacept or rituximab-pvvr followed by placebo.

Schedule of Visits

  • Screening Visit
  • Treatment Phase – 15 visits over about 24 months
  • Follow-Up Phase – 5 visits over about 24 months

IRB: STUDY21040103A
- Rituximab-pvvr followed by Abatacept verses Rituximab-pvvr Alone in New Onset Type 1 Diabetes

RESEARCH AREAS & CONDITIONS:
  Healthy Aging


PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/relay and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Ingrid Libman DeGordon

Ingrid Libman DeGordon, MD, PhD, is an Associate Professor in the Division of Pediatric Endocrinology at the University of Pittsburgh School of Medicine and Director of the UPMC Children’s Hospital of Pittsburgh Diabetes Program. A graduate of the University of Pittsburgh Graduate School of Public Health, Dr. Libman’s research interests include prediction, prevention and management of diabetes in youth, the impact of obesity in type 1 diabetes and the concept of “double” diabetes in childhood.